Precision BioSciences Inc., a clinical stage gene editing company, has announced the results of Phase 1 safety and efficacy for Cohort 1 in the ELIMINATE-B trial, evaluating PBGENE-HBV for chronic hepatitis B. This first-in-human trial involves patients who are HBeAg-negative and treated with nucleos(t)ide analog therapies. Data from Cohort 1, administered at the lowest dose level of 0.2 mg/kg, has been collected as of the cutoff on July 28, 2025. Initial safety data from Cohort 2, dosed at 0.4 mg/kg, has also been released. Further clinical development will be supported by Mark Sulkowski, M.D. of Johns Hopkins University, who has expanded his advisory role to optimize trial strategies for PBGENE-HBV.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.